Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

Hope S. Rugo1 · Eduardo J. Pennella2,3 · Unmesh Gopalakrishnan4 · Miguel Hernandez-Bronchud5 · Jay Herson6 · Hans Friedrich Koch7 · Subramanian Loganathan8 · Sarika Deodhar8 · Ashwani Marwah8 · Alexey Manikhas9 · Igor Bondarenko10 · Guzel Mukhametshina11 · Gia Nemsadze12 · Joseph D. Parra13 · Maria Luisa T. Abesamis-Tiambeng14 · Kakhaber Baramidze15 · Charuwan Akewanlop16 · Ihor Vynnychenko17 · Virote Sriuranpong18 · Gopichand Mamillapalli19 · Sirshendu Roy20 · Eduardo Patricio Yanez Ruiz21 · Abhijit Barve2 · Adolfo Fuentes-Alburo2 · Cornelius F. Waller22

Abstract

Purpose The phase 3 HERITAGE trial demonstrated that the biosimilar trastuzumab-dkst is well tolerated with similar efficacy (measured by overall response rate [ORR] and progression-free survival [PFS]) compared with originator trastuzumab combined with taxane followed by monotherapy in patients with HER2-positive metastatic breast cancer (MBC). Herein, we present final overall survival (OS) from HERITAGE.

Methods HERITAGE is a multicenter, double-blind, randomized, parallel-group study. Patients were randomized 1:1 to receive trastuzumab-dkst or trastuzumab plus taxane followed by continued monotherapy until disease progression. Overall survival was to be assessed at 36 months or after 240 deaths, whichever occurred first, as observed from time of randomization of last patient.

Results At the final analysis (36 months), 242 patients in the intention-to-treat population had died during the study: 116 and 124 in the trastuzumab-dkst and trastuzumab groups, respectively, and 1 untreated patient from each treatment group. Median OS by Kaplan–Meier analysis was 35.0 months with trastuzumab-dkst and 30.2 months with trastuzumab. Evaluation of PFS showed a median of 11.1 months in both treatment groups. No new safety concerns were reported from week 48 until the end of the survival follow-up.

Conclusion This is the first phase 3 trial of a trastuzumab biosimilar to report long-term survival data similar to originator trastuzumab in patients with MBC. The comparable long-term OS between the trastuzumab-dkst and originator trastuzumab groups further supports the similarity of trastuzumab-dkst with originator trastuzumab and establishes trastuzumab-dkst as a safe and effective treatment option for patients with HER2-positive MBC.

ClinicalTrials.gov NCT02472964; 6/16/2015

Keywords Biosimilar · Metastatic breast cancer · Trastuzumab · Overall survival

Introduction

Monoclonal antibodies (mAbs) against tumor-associated markers have been established as safe and effective cancer therapies for several decades [1–4]. Despite therapeutic success, global access to mAbs is limited by the high costs associated with biologic therapies [5–7]. Because of these limitations, there has been an increasing interest in the development of biosimilar agents to provide cost-effective alternatives to expensive biologic cancer therapies [6, 8].

Worldwide, breast cancer is one of the most frequently diagnosed cancers in women, accounting for > 2 million new cancer cases in 2018 [9]. The oncoprotein HER2 is amplified in 15% to 30% of invasive breast cancers (HER2-positive), leading to uncontrolled cell proliferation and tumorigenesis.
Trastuzumab (Herceptin®; Genentech Inc, South San Francisco, CA), a humanized IgG1 mAb directed against HER2, was initially approved in 1998 in the United States for the treatment of HER2-overexpressing breast cancer [11]. Combined with chemotherapy, trastuzumab has been associated with significantly improved overall survival (OS) and progression-free survival (PFS), higher overall response rate (ORR), and longer duration of response (DR) in patients with HER2-positive metastatic breast cancer [12].

With the recent patent expirations of trastuzumab in the European Union (2014) and United States (2019), several trastuzumab biosimilars have been developed [13, 14]. Recently, the trastuzumab biosimilar trastuzumab-dkst (Ogivri®; Viatris Inc, Canonsburg, PA) was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of HER2-overexpressing breast cancer and metastatic gastric or gastroesophageal junction cancer [13, 15]. Approval was based on robust analytical and pharmacokinetic (PK) data, as well as the results of the HERITAGE trial, a phase 3 study comparing the safety, tolerability, and efficacy of trastuzumab-dkst and trastuzumab in patients with HER2-positive metastatic breast cancer [16–18].

As previously reported, results from the phase 3 HERITAGE trial demonstrated that the ORR was equivalent between trastuzumab-dkst and trastuzumab each in combination with taxane-based chemotherapy at 24 weeks [16]. After combination therapy, patients with stable disease continued their assigned monotherapy until disease progression, unacceptable toxicity, or death, whichever occurred first. No significant differences in ORR, PFS, or interim OS were observed between the trastuzumab-dkst and trastuzumab groups at week 48. Week 24 ORR was highly correlated with PFS at week 48, indicating similarity of the 2 therapies and supporting the use of ORR as a valid endpoint in clinical trials for metastatic breast cancer [19]. We now present the results of the final OS analysis after 36 months and overall safety analysis of the HERITAGE trial.

Methods

This was a multicenter, double-blind, randomized, parallel-group, phase 3 study (ClinicalTrials.gov, NCT02472964) in patients with HER2-positive metastatic breast cancer conducted in accordance with the International Council for Harmonisation Guidance for Industry E6 Good Clinical Practice, the Declaration of Helsinki, and applicable local regulatory requirements. All patients provided written informed consent before starting any study-related procedures. The full trial protocol and all other relevant study documentation were approved by the institutional review board or ethics committee at each study center before study initiation.

Eligibility

Full inclusion and exclusion criteria have been previously reported [16]. Eligible patients were adults with histologically confirmed HER2-positive breast cancer having ≥1 measurable metastatic lesion. Key eligibility criteria included an Eastern Cooperative Oncology Group performance status of 0 to 2 and left ventricular ejection fraction (LVEF) within normal range [16]. Patients must not have received chemotherapy or HER2-targeted therapy within 1 year of diagnosis of metastatic disease.

Study design

Details of the study design and dosing schedules have been previously reported (Online Resource 1) [16]. Briefly, patients were randomly assigned 1:1 to receive taxane of institutional choice (docetaxel or paclitaxel) plus trastuzumab-dkst or trastuzumab for 8 cycles (24 weeks). Patients with at least stable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) at week 24 could continue with monotherapy mAb treatment according to their original randomization until progression, discontinuation due to unacceptable toxicity, or death. At the end of treatment, patients were followed every 3 months for 36 months from the date of randomization or death to assess survival. The secondary objective of this phase 3 study was to assess OS at 36 months or after 240 deaths, whichever occurred first, as observed from the time of randomization of the last patient.

Efficacy evaluation

Overall survival was defined as the time from randomization to date of death due to any cause and was cumulative through 36 months of follow-up. The endpoints for the primary and secondary study objectives (ie, ORR, PFS) were analyzed at week 24 for the combination therapy phase and at week 48 for the monotherapy phase, and have been previously reported [16, 19]. In this analysis, efficacy endpoints were reported in all patients who enrolled after the second protocol amendment (intention-to-treat population [ITT]), which excluded patients who had already received first-line therapy.

Safety

The safety population included all patients who received ≥1 dose of trastuzumab-dkst or trastuzumab. Assessment of treatment-emergent adverse events (TEAEs) included type,
incidence, severity (graded by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03), timing, seriousness, and relatedness. Safety analyses also included assessment of LVEF values. Safety during combination and monotherapy has been previously reported [16, 19]. This report includes assessment of any updates observed through the final analysis, including accumulated data on AEs of special interest.

**Statistical analysis**

Details on sample size have been previously reported [16]. Clinical activity was evaluated by assessing progression of disease, defined according to RECIST v1.1. Descriptive statistics were used to summarize patient disposition, baseline characteristics, and treatment administration, and SAS® software version 9.2 or later (SAS, Cary, NC) was used for analysis. For OS and PFS, Kaplan–Meier plots by treatment group were presented, and the log-rank test of the 2 groups unadjusted for covariates was performed.

**Results**

**Patient disposition and baseline characteristics**

Of the 500 randomized patients, 249 were randomized to receive trastuzumab-dkst and 251 were randomized to receive trastuzumab, each in combination with taxane. The ITT population, used to evaluate efficacy, was composed of 458 female patients (230 randomized to trastuzumab-dkst and 228 randomized to trastuzumab) who had not previously received first-line therapy (Fig. 1). The mean (SD) age of patients was slightly lower in the trastuzumab group (52.9 ± 11.2) than in the trastuzumab-dkst group (54.3 ± 11.0). Demographics and baseline characteristics for both treatment groups were similar with respect to age, race, height, weight, body surface area, exposure to prior therapies, and time since diagnosis and were unchanged compared with the week 48 analyses (Table 1) [19]. The safety population was composed of 493 patients, defined

**Fig. 1** Patient CONSORT diagram for the intention-to-treat population in the HERITAGE trial
as those who received ≥ 1 dose of study drug, regardless of whether they had received prior first-line therapy.

After combination therapy, 343 patients entered the monotherapy phase for safety analysis (trastuzumab-dkst, N = 179; trastuzumab, N = 164). The demographic profile for patients with safety monotherapy data is consistent with that for the ITT efficacy population. At the time of the final OS analysis, 169 patients in the safety population had received further lines of therapy (Online Resource 2), with similar distribution of HER2-targeted treatments (15.6% [n = 28] vs 18.9% [n = 31]), endocrine therapies (9.5% [n = 17] vs 14.6% [n = 24]), and chemotherapies (30.2% [n = 54] vs 25.0% [n = 41]) in the trastuzumab-dkst and trastuzumab groups, respectively.

### Efficacy evaluation

At the time of final analysis, 242 patients had died during the study: 116 patients treated with trastuzumab-dkst, 124 patients treated with trastuzumab, and 2 untreated patients (1 patient from each group). At final assessment, 121 (52.6%) patients were alive in the trastuzumab-dkst group, and 114 (50.0%) patients were alive in the trastuzumab group (including 79 [trastuzumab-dkst] and 75 [trastuzumab] patients who received monotherapy during the study). The survival curves did not significantly differ between treatment groups (P = 0.427; Fig. 2). The median OS by Kaplan–Meier analysis was 35.0 months in the trastuzumab-dkst group and 30.2 months in the trastuzumab group. Overall median

### Table 1 Demographics and baseline characteristics: ITT population

| Parameter                        | Patients, n (%) |
|----------------------------------|-----------------|
|                                 | Trastuzumab-dkst | Trastuzumab |
|                                 | (N = 230)       | (N = 228)   |
| Age, mean (SD), years            | 54.3 (11.0)     | 52.9 (11.2) |
| Race, n (%)                      |                 |             |
| Asian                            | 70 (30.4)       | 72 (31.6)   |
| Black or African American        | 1 (0.4)         | 2 (0.9)     |
| White                            | 159 (69.1)      | 154 (67.5)  |
| Height, mean (SD), cm            | 159.0 (7.1)     | 159.3 (7.6) |
| Weight, mean (SD), kg            | 68.4 (15.0)     | 68.9 (16.0) |
| BSA, mean (SD), m²               | 1.73 (0.21)     | 1.73 (0.22) |
| Assigned taxane, n (%)           |                 |             |
| Docetaxel                        | 193 (83.9)      | 192 (84.2)  |
| Paclitaxel                       | 35 (15.2)       | 32 (14.0)   |
| No treatment                     | 2 (0.9)         | 4 (1.8)     |
| ER + or PR +, n (%)              | 102 (44.3)      | 101 (44.3)  |
| Prior treatment, n (%)           |                 |             |
| Trastuzumab                      | 22 (9.6)        | 16 (7.0)    |
| Taxane                           | 46 (20.0)       | 42 (18.4)   |
| Time from diagnosis to metastatic disease, n (%) | | |
| <2 years                         | 146 (63.5)      | 153 (67.1)  |
| ≥2 years                         | 75 (32.6)       | 71 (31.1)   |

BSA body surface area, ER+ estrogen receptor–positive, PR+ progesterone receptor–positive
follow-up time was 32.6 months (35.7 months in the trastuzumab-dkst group and 31.1 months in the trastuzumab group). The 95% CI of the hazard ratio (HR) for OS included “1” for both trastuzumab-dkst and trastuzumab at the time of the final analysis, indicating no relevant differences in survival benefit between treatment groups.

At final assessment, 82 (35.7%) patients in the trastuzumab-dkst group were free of progression compared with 86 (37.7%) patients in the trastuzumab group. The time-to-event curves for both treatment groups were not statistically significantly different ($P = 0.864$; Fig. 3). As with OS, the 95% CI of the OS ratio (trastuzumab-dkst to trastuzumab) included “1” for all subgroups at the time of the final analysis, and hence, no relevant differences between subgroups were observed. However, tumor endocrine status (negative vs positive; HR 1.40; $P = 0.017$), race (Black vs White and Asian vs White; HR 3.71 and 1.38, respectively; $P = 0.011$), previous adjuvant/neoadjuvant chemotherapy/HER2-targeted therapy (yes vs no; HR 1.39; $P = 0.016$), and number of metastatic sites (2 vs 1, 3 vs 1, and ≥4 vs 1; HR 1.44, 1.51, and 2.46, respectively; $P < 0.001$) had an effect on OS. The treatment HR (95% CI) adjusted for these factors was 0.85 (0.653–1.116; $P = 0.248$). Median PFS was 11.1 months in both treatment groups. Duration of response was also not statistically different between treatment groups ($P = 0.771$), with 123 (64.1%) patients in the trastuzumab-dkst group having tumor progression or dying before the final analysis, compared with 119 (64.7%) patients in the trastuzumab group. Median DR was 9.9 months in the trastuzumab-dkst group and 9.8 months in the trastuzumab group. Sensitivity analyses of all enrolled patients showed that OS, PFS, and DR results were similar to those observed in the ITT population that included patients who had received prior first-line therapy.

**Safety and tolerability**

Safety and tolerability analyses for the combination therapy and monotherapy phases of the trial were previously reported [16, 19]. From the initiation of the monotherapy phase through final analysis, the number of patients with ≥1 TEAE was similar between the trastuzumab-dkst (69.3% [$n = 124$]) and trastuzumab groups (72.6% [$n = 119$]). Most TEAEs occurred in similar numbers in the trastuzumab-dkst and trastuzumab groups, except for patients experiencing anemia (3.4% [$n = 6$] and 10.4% [$n = 17$], respectively), and were generally grade 1 or 2 in severity (Table 2). Overall incidence of serious AEs (SAEs) reported from the start of the monotherapy phase through the end of the trial was 5.8% ($n = 20$). Incidence of SAEs was similar between the trastuzumab-dkst and trastuzumab groups, except for patients experiencing anemia (3.4% [$n = 6$] and 10.4% [$n = 17$], respectively), and were generally grade 1 or 2 in severity (Table 2). Overall incidence of serious AEs (SAEs) reported from the start of the monotherapy phase through the end of the trial was 5.8% ($n = 20$). Incidence of SAEs was similar between the trastuzumab-dkst and trastuzumab groups, except for patients experiencing anemia (3.4% [$n = 6$] and 10.4% [$n = 17$], respectively), and were generally grade 1 or 2 in severity (Table 2). Overall, 8 (2.3%) patients withdrew from the study because of 1 or more TEAEs, 4 (2.2%) in the trastuzumab-dkst group and 4 (2.4%) in the trastuzumab group. Throughout the entire study, 57 patients (23.1%) in the figure. The stratified hazard was calculated by assigned taxane, tumor progression, and tumor endocrine status
the trastuzumab-dkst group and 58 patients (23.6%) in the trastuzumab group reported TEAEs of special interest, including infusion reactions (6.9% \(n=17\), 4.9% \(n=12\)) and hypersensitivity events (2.4% \(n=6\), 3.7% \(n=9\)). Few patients in each treatment group had observed LVEF values of < 50% at least once post-baseline (trastuzumab-dkst, 4.5% \(n=11\); trastuzumab, 3.3% \(n=8\)).

As previously reported, only 2 fatal TEAEs were reported in the monotherapy phase, both unrelated to the study drug [19]. There were no additional fatal TEAEs after week 48 and no new safety concerns reported through the end of the survival follow-up.

**Discussion**

Previously reported efficacy analyses from the HERITAGE trial have demonstrated similarity between reference trastuzumab and trastuzumab-dkst by comparing the endpoints OS, PFS, DR, and time to progression over 48 weeks [19]. Additionally, these studies showed a strong positive correlation between ORR at week 24 and PFS at week 48. Incidence and nature of TEAEs and SAEs were also similar between the trastuzumab-dkst and trastuzumab groups through 48 weeks [19]. After these analyses, patients were followed every 3 months for 36 months to allow for assessment of OS. This is the first phase 3 trial of a trastuzumab biosimilar to report long-term survival data similar to those for originator trastuzumab in patients with metastatic breast cancer, confirming the use of a short-term endpoint (ORR) in a sensitive population to define and determine biosimilarity.

The comparable OS between the trastuzumab-dkst (35.0 months) and originator trastuzumab (30.2 months) treatment groups further supports previously reported similarity between the safety and efficacy profiles of the biosimilar and reference agents [19]. At the final assessment, approximately 50% of patients in each treatment group were alive, and survival curves for both groups were not significantly different \((P=0.427)\). These results support the long-term use of biosimilar trastuzumab in the metastatic setting. Recent evidence has also demonstrated the long-term efficacy of another trastuzumab biosimilar (SB3) in the neoadjuvant setting [20]. A phase 3 extension study aimed to assess long-term survival in patients with HER2-positive early breast cancer treated with SB3 or originator trastuzumab over 5 years. At the 3-year follow-up, the study reported similar OS rates between the biosimilar (97.0%) and originator (92.9%) trastuzumab treatment groups [20]. At the end of the study, all patients still on monotherapy were offered continued therapy and access to trastuzumab-dkst. Additional use of cancer treatments in both groups was similar. At 36 months, 169 of 343 patients in the safety population receiving monotherapy had received further lines of therapy, with similar distribution of HER2-targeted treatments between groups. However, the overall use of further lines of therapy was low, possibly due to limited accessibility and cost. It is possible that this limited use of further lines of treatment may help to explain the relatively lower OS observed in the trastuzumab-dkst and trastuzumab groups in this study compared with OS reported in recent publications [21, 22]. For example, in the CLEOPATRA trial assessing OS in patients with HER2-positive metastatic breast cancer.

### Table 2: TEAEs in patients who continued on monotherapy (≥ 5% in Either Treatment Group)

| TEAEs, n (%) | Patients, n (%) |
|-------------|----------------|
|             | Trastuzumab-dkst (N=179) | Trastuzumab (N=164) |
|             | All grades | Grade ≥ 3 | All grades | Grade ≥ 3 |
| Any TEAE    | 124 (69.3) | 23 (12.8) | 119 (72.6) | 31 (18.9) |
| Headache    | 19 (10.6)  | 0       | 23 (14.0)  | 4 (2.4)   |
| Hypertension| 12 (6.7)   | 2 (1.1)  | 9 (5.5)    | 1 (0.6)   |
| Increased ALT| 11 (6.1) | 2 (1.1) | 7 (4.3) | 3 (1.8) |
| Vomiting    | 10 (5.6)   | 0       | 7 (4.3)    | 0         |
| Decreased ejection fraction | 10 (5.6) | 0 | 6 (3.7) | 1 (0.6) |
| Upper respiratory tract infection | 10 (5.6) | 0 | 4 (2.4) | 0 |
| Increased AST| 9 (5.0) | 1 (0.6) | 7 (4.3) | 3 (1.8) |
| Fatigue     | 9 (5.0)    | 0       | 7 (4.3)    | 0         |
| Arthralgia  | 9 (5.0)    | 0       | 3 (1.8)    | 0         |
| Cough       | 9 (5.0)    | 0       | 3 (1.8)    | 0         |
| Anemia      | 6 (3.4)    | 0       | 17 (10.4)  | 2 (1.2)   |
| Peripheral neuropathy | 5 (2.8) | 0 | 9 (5.5) | 0 |

*ALT alanine aminotransferase, AST aspartate aminotransferase*
receiving trastuzumab combined with either pertuzumab plus chemotherapy or placebo plus chemotherapy, median OS in patients receiving trastuzumab combined with placebo plus chemotherapy was 40.8 months [21]. In another previously published, prospective study of first-line therapy with trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer, median OS was 37.1 months [22].

In addition to comparable OS between the trastuzumab-dkst and trastuzumab groups observed in the present study, at the time of final analysis, other efficacy endpoints, including PFS and DR, demonstrated similarity. Together, these results are consistent with previous reports from the primary analysis at 24 weeks and further support the conclusion of therapeutic equivalence [16].

Safety results from the primary analysis indicated that there were no notable differences between the trastuzumab-dkst and trastuzumab treatment groups in incidence or severity of TEAEs [16, 19]. Safety profiles remained similar over the 48-week monotherapy phase and through the long-term assessment, with no new safety concerns observed [19].

Limitations of the HERITAGE trial are consistent with other biosimilar clinical development programs, including the use of a short-term primary efficacy endpoint to initially assess similarity between trastuzumab-dkst and reference trastuzumab. Assessment of ORR at 24 weeks was chosen as the primary endpoint as a short-term measure of clinical activity and safety related to the use of trastuzumab-dkst as first-line therapy for metastatic breast cancer. The long-term assessment of OS and safety builds upon previously reported efficacy results and supports the use of trastuzumab-dkst in patients with HER2-positive metastatic breast cancer. However, the summary of the secondary endpoints must be interpreted with caution as the analysis was not statistically powered. The $P$ values presented for subgroup and secondary analyses should therefore be considered as a flagging indicator to show the differences among the collected data. The study was powered to determine equivalence between trastuzumab-dkst and reference trastuzumab at 24 weeks.

Biosimilars play a key role in reducing healthcare costs and improving patient access to life-saving therapies [6]. Results from a previous study have suggested that the use of trastuzumab biosimilars compared with originator trastuzumab may lead to annual cost savings in the range of 96 to 120 million euros (~11%) in a country like Germany [23]. The long-term data presented here further support trastuzumab-dkst as a valuable part of the growing biosimilar market that includes 4 other trastuzumab biosimilars approved by the FDA and EMA in recent years [13]. As such, trastuzumab-dkst is a safe and efficacious treatment option for patients with HER2-positive metastatic breast cancer and metastatic gastric cancer.

**Conclusion**

In patients with HER2-positive metastatic breast cancer, treatment with trastuzumab-dkst and originator trastuzumab led to similar OS cumulative through 36 months of follow-up. This is the first phase 3 trastuzumab biosimilar trial to report similar long-term survival data in metastatic breast cancer. No notable differences were observed between treatment groups in other efficacy endpoints, including PFS and DR. Furthermore, there were no clinically meaningful differences in safety profiles between treatment groups and no new safety signals observed after week 48. Together, these results further support the similarity of trastuzumab-dkst with originator trastuzumab and establish this biosimilar as a safe, effective, and affordable treatment option for patients with HER2-positive metastatic breast cancer and metastatic gastric cancer.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s10549-021-06197-5.

**Acknowledgements** Financial support for this study was provided by Viatris Inc, Canonsburg, PA, and Biocon Limited, Bangalore, India. Editorial assistance was provided under the direction of the authors by MedThink SciCom, with support from Viatris Inc.

**Funding** This study was funded by Viatris Inc, Canonsburg, PA, and Biocon Limited, Bangalore, India.

**Data availability** The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Conflict of interest** HS Rugo has received travel, accommodations, and expenses from Amgen, Merck, Viatris Inc, Pfizer, and Puma Biotechnology and research funding (provided to the Regents of the University of California) from Eisai, Genentech/Roche, Lilly, Macrogenics, Merck, Novartis, OBI Pharma, Daiichi, Immunomedics, and Pfizer. EJ Pennella was a paid employee of Mylan Inc (now Viatris Inc) during the time of the study and may hold stock with the company. U Gopalakrishnan, K Beckmann, HF Koch, A Barve, and A Fuentes-Alburo are paid employees of Viatris Inc and may hold stock with the company. M Hernandez-Bronchud has served as a consultant/advisory board member for Viatris Inc. S Loganathan, S Deodhar, and A Marwah are paid employees of Biocon Research Ltd and may hold stock with the company. C Akewanlop has received travel, accommodations, and expenses from Amgen, AstraZeneca, Roche, and Bristol-Myers Squibb. CF Waller is a consultant/advisory board member for Viatris Inc. J Herson, A Manikhas, I Bondarenko, G Mukhametshina, G Nem sadze, JD Parra, MLT Abesamis-Tiambeng, K Baramidze, I Vy mychenko, V S L Siriuranpong, G Mamillapalli, S Roy, and EP Yanez Ruiz have nothing to disclose.

**Ethical approval** This study was conducted in accordance with the International Council for Harmonisation Guidance for Industry E6 Good Clinical Practice, the Declaration of Helsinki, and applicable local regulatory requirements. All patients provided written informed consent before starting any study-related procedures. The full trial
protocol and all other relevant study documentation were approved by the institutional review board or ethics committee at each study center before study initiation.

**Consent to participate** All patients provided written informed consent before starting any study-related procedures.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Sharkey RM, Goldenberg DM (2006) Targeted therapy of cancer: new prospects for antibodies and immunocogjugates. CA Cancer J Clin 56:226–243. https://doi.org/10.3322/canclin.56.4.226
2. Eisenbeis AM, Grau SJ (2012) Monoclonal antibodies and Fc fragments for treating solid tumors. Biologics 6:13–20. https://doi.org/10.2147/BBT.S19955
3. Scott AM, Allison JP, Wolchok JD (2012) Monoclonal antibodies in cancer therapy. Cancer Immun 12:14
4. Bellati F, Napoletano C, Gasparri ML, Visconti V, Zizzari IG, Ruscito I, Caccetta J, Rugghetti A, Benedetti-panic P, Nuti M (2011) Monoclonal antibodies in gynecological cancer: a critical point of view. Clin Dev Immunol 2011:890758. https://doi.org/10.1155/2011/890758
5. Lammers P, Criscitiello C, Curigliano G, Jacobs I (2014) Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets. Pharmaceuticals (Basel) 7:943–953. https://doi.org/10.3390/ph7090943
6. Rugo HS, Linton KM, Cervi P, Rosenberg JA, Jacobs I (2016) A clinician’s guide to biosimilars in oncology. Cancer Treat Rev 46:73–79. https://doi.org/10.1016/j.ctrv.2016.04.003
7. McCamish M, Woollett G (2011) Worldwide experience with biosimilar development. Mabs 3:209–217. https://doi.org/10.4161/mabs.3.2.15005
8. Nixon NA, Hannous MB, Verma S (2018) The evolution of biosimilars in oncology, with a focus on trastuzumab. Curr Oncol 25(suppl 1):S171–S179. https://doi.org/10.3747/co.25.3942
9. Ferlay J, Colombot M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953. https://doi.org/10.1002/ijc.31937
10. Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014:852748. https://doi.org/10.1155/2014/852748
11. Herceptin [package insert] (2017) Novelty GmbH, Zurich. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5256s1bpl.pdf. Accessed 8 Jun 2021
12. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792. https://doi.org/10.1056/NEJM200103131450710
13. Barbier L, Declerck P, Simoens S, Neven P, Vulto AG, Huys I (2019) The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. Br J Cancer 121:199–210. https://doi.org/10.1038/s41416-019-0480-z
14. Chopra R, Lopes G (2017) Improving access to cancer treatments: the role of biosimilars. J Glob Oncol 3:596–610. https://doi.org/10.1200/JGO.2016.008607
15. Ogivri [package insert] (2017) Mylan GmbH, Zurich. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761074s000lbl.pdf. Accessed 8 Jun 2021
16. Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, Sharma R, Baczkowski M, Kothehar M, Loganathan S, Manikas A, Bondarenko I, Mukhametshina G, Nemsadze G, Parra JD, Abesamis-Tiamemb MLT, Baramidze K, Akewanlop C, Vynnychenko I, Siurangpong V, Ramilapa G, Ray S, Yanez REP, Pennella E, and the Heritage Study Investigators (2017) Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA 317:37–47. https://doi.org/10.1001/jama.2016.18305
17. Chitouli H, Valloton L, Audran D, Dao K, Rothuizen LE, Winterfeld U, Appenzeller-Maghrroui A, Bamford R, Battle A, Pennella E, Brunner-Ferber F, Spertini F, Bucin T (2015) A bioequivalence study for Hercules, a biosimilar trastuzumab candidate in phase II development [BPS 292P]. Abstract presented at the British Pharmacological Society 2015; London, UK. http://www.bps201online.org/abstract abstract.jsp?abid=32951. Accessed 18 Dec 2020
18. Waller CF, Vutikullid A, Lawrence TE, Shaw A, Liu MS, Baczkowski M, Sharma R, Barve A, Goyal P, Donnelly C, Sengupta N, Pennella EJ (2018) A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-14010 vs. EU-trastuzumab and US-trastuzumab. Br J Clin Pharmacol 84:2336–2343. https://doi.org/10.1111/bcp.13689
19. Manikhas A, Pennella EJ, Bondarenko I, Mukhametshina G, Abesamis-Tiamemb MLT, Akewanlop C, Vynnychenko I, Siurangpong V, Ray S, Waller CF, Hernandez Bronchud M, Herson J, Loganathan S, Barve A, Rugo HS (2018) Biosimilar trastuzumab-dkt monotherapy versus trastuzumab monotherapy after combination therapy: toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial at 48 weeks of follow-up. Slides presented at the American Society of Clinical Oncology Annual Meeting; June 1–5, 2018; Chicago, IL
20. Pivot X, Pegram M, Cortes J, Lüftner D, Lyman GH, Curigliano G, Bondarenko I, Yoon YC, Kim Y, Kim C (2019) Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. Eur J Cancer 120:1–9. https://doi.org/10.1016/j.ejca.2019.07.015
21. Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortes J, and the CLEOPATRA Study Group (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: a randomized clinical trial. JAMA 317:37–47. https://doi.org/10.1056/NEJMoa1413513
22. Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crow J, Mackey JR, Furneau P, Rolski J, Mrsic-Krmptotic Z, Jagiello-Gruszfeld A, Riva A, Bays M, Taupin H, Sauter G, Press MF, Slamon DJ (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active
therapeutic regimens. J Clin Oncol 29:149–156. https://doi.org/10.1200/JCO.2010.28.6450
23. Hübel K, Kron F, Lux MP (2020) Biosimilars in oncology: effects on economy and therapeutic innovations. Eur J Cancer 139:10–19. https://doi.org/10.1016/j.ejca.2020.07.037

Authors and Affiliations

Hope S. Rugo1 • Eduardo J. Pennella2,3 • Unmesh Gopalakrishnan4 • Miguel Hernandez-Bronchud5 • Jay Herson6 • Hans Friedrich Koch7 • Subramanian Loganathan8 • Sarika Deodhar8 • Ashwani Marwah8 • Alexey Manikhas9 • Igor Bondarenko10 • Guzel Mukhametshina11 • Gia Nemsadze12 • Joseph D. Parra13 • Maria Luisa T. Abesamis-Tiambeng14 • Kakhaber Baramidze15 • Charuwan Akewanlop16 • Ihor Vynnychenko17 • Virote Sriuranpong18 • Gopichand Mamillapalli19 • Sirshendu Roy20 • Eduardo Patricio Yanez Ruiz21 • Abhijit Barve2 • Adolfo Fuentes-Alburo2 • Cornelius F. Waller22

1 University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
2 Viatris Inc, Canonsburg, PA, USA
3 Present Address: MaxCyte, Inc, Gaithersburg, MD, USA
4 Viatris Inc, Bangalore, India
5 GénesisCare Corachan, Barcelona, Spain
6 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
7 Viatris Inc, Hannover, Germany
8 Biocon Research Limited, Bangalore, India
9 City Clinical Oncology Dispensary, Saint Petersburg, Russia
10 Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine
11 Regional Clinical Oncological Center, Kazan, Russia
12 Institute of Clinical Oncology, Tbilisi, Georgia
13 St Luke’s Medical Center, Quezon City, Philippines
14 Cardinal Santos Medical Center, Manila, Philippines
15 Golden Fleece 21 Century Health House Ltd, Tbilisi, Georgia
16 Siriraj Hospital, Bangkok, Thailand
17 Sumy State University, Sumy, Ukraine
18 King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
19 City Cancer Center, Vijayawada, India
20 Curie Manavata Cancer Centre, Nasik, India
21 Universidad de la Frontera, Temuco, Chile
22 Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg and Faculty of Medicine, University of Freiburg, Freiburg, Germany